Reply to: “Comment on ‘Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis'”

Research output: Contribution to journalLetterResearchpeer-review

Original languageEnglish
JournalJournal of the American Academy of Dermatology
Volume85
Issue number6
Pages (from-to)e379
ISSN0190-9622
DOIs
Publication statusPublished - 2021

ID: 301440685